Whereas VEGF inhibitors alone show promising effects in the treatment of HCC, our study suggests an additional novel role for DDAH-targeted therapy in HCC to significantly improve clinical outcome in HCC patients. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.